Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 18/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.68 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.68 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.68 |
| ▸ | BMX | P51813 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16137329 | 0.97 | FGFR4 (0.75) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16137337 | 0.89 | FGFR4 (0.75) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16072036 | 0.89 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16071493 | 0.88 | FGFR4 (0.81) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16137322 | 0.88 | FGFR4 (0.72) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16137292 | 0.86 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16071424 | 0.86 | FGFR4 (0.72) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16071754 | 0.85 | FGFR4 (0.76) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16137323 | 0.85 | FGFR4 (0.68) | FGFR4FGFR1FGFR2FGFR3BMX | |
| SCHEMBL16071706 | 0.85 | FGFR4 (0.83) | FGFR4FGFR1FGFR2FGFR3BMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663524-B2 | Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors | CELGENE CAR LLC (BM) | 2017-05-30 | — | — | US | disclosed |
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046634-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885FGFR1 1733/4885FGFR2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.